NCT01476592

A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

Completed NA Last updated 14 November 2019

What this trial tests

NA trial testing Resveratrol in Neuroendocrine Tumor in 7 participants. Completed in 11 October 2018.

Timeline

1 December 2011

Primary endpoint
1 October 2013

11 October 2018

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	1 December 2011
Primary completion	1 October 2013
Estimated completion	11 October 2018
Sites	1 location across United States

Drugs / interventions tested

• Resveratrol — full drug profile →

Conditions studied

• Neuroendocrine Tumor — all drugs for Neuroendocrine Tumor →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels
  Time frame: 1 year
  1\. The investigators aim primarily to show that resveratrol therapy in patients with low-grade GI neuroendocrine tumors will significantly increase Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels. Endpoints: The primary endpoint will be the level of expression of full length Notch1, cleaved Notch1, HES-1, and ASCL-1, as measured by Western blot usi

Sponsor's own description

Resveratrol has been shown to activate a protein called Notch-1. Signaling of Notch-1 has been shown to prevent tumor cell growth. Resveratrol has also been shown to prevent growth of tumors in mice. The purpose of this study is to examine the effects of resveratrol and Notch-1 on neuroendocrine tumor tissue and to examine how people with neuroendocrine tumors who take resveratrol for up to three months tolerate the product.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.
   Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, et al · · 2019 · cited 560× · PMID 32116665 · DOI 10.3389/fphar.2019.01614
2. Natural Products as Anticancer Agents: Current Status and Future Perspectives.
   Naeem A, Hu P, Yang M, Zhang J, et al · · 2022 · cited 292× · PMID 36500466 · DOI 10.3390/molecules27238367
3. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy.
   Dehelean CA, Marcovici I, Soica C, Mioc M, et al · · 2021 · cited 244× · PMID 33669817 · DOI 10.3390/molecules26041109
4. Anticancer Molecular Mechanisms of Resveratrol.
   Varoni EM, Lo Faro AF, Sharifi-Rad J, Iriti M. · · 2016 · cited 231× · PMID 27148534 · DOI 10.3389/fnut.2016.00008
5. Resveratrol and cancer: Challenges for clinical translation.
   Singh CK, Ndiaye MA, Ahmad N. · · 2015 · cited 176× · PMID 25446990 · DOI 10.1016/j.bbadis.2014.11.004
6. ROS-Mediated Cancer Cell Killing through Dietary Phytochemicals.
   NavaneethaKrishnan S, Rosales JL, Lee KY. · · 2019 · cited 116× · PMID 31217841 · DOI 10.1155/2019/9051542
7. Antioxidant Therapy in Cancer: Rationale and Progress.
   Luo M, Zhou L, Huang Z, Li B, et al · · 2022 · cited 109× · PMID 35740025 · DOI 10.3390/antiox11061128
8. Regulation of microRNAs by natural agents: new strategies in cancer therapies.
   Phuah NH, Nagoor NH. · · 2014 · cited 90× · PMID 25254214 · DOI 10.1155/2014/804510